Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cb9f654ff-k7rjm Total loading time: 0 Render date: 2025-08-10T12:12:09.445Z Has data issue: false hasContentIssue false

Chapter 10 - Management of autonomic dysfunction in Parkinson's disease

from Section II - Management of Nonmotor Symptoms of Parkinson's Disease

Published online by Cambridge University Press:  05 March 2016

By
Shen-Yang Lim  and
Ai Huey Tan
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 93 - 110
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Postuma, RB, Gagnon, JF, Pelletier, A, Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord 2013; 28: 597–604.CrossRefGoogle ScholarPubMed
Muller, B, Larsen, JP, Wentzel-Larsen, T, Skeie, GO, Tysnes, OB, Parkwest Study Group. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011; 26: 65–72.CrossRefGoogle ScholarPubMed
Gallagher, DA, Lees, AJ, Schrag, A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25: 2493–500.CrossRefGoogle Scholar
Stubendorff, K, Aarsland, D, Minthon, L, Londos, E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One 2012; 7: e45451.CrossRefGoogle ScholarPubMed
Perez-Lloret, S, Rey, MV, Pavy-Le Traon, A, Rascol, O. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerging Drugs 2013; 18: 39–53.CrossRefGoogle ScholarPubMed
Pfeiffer, RF. Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother 2012; 12: 697–706.CrossRefGoogle ScholarPubMed
Ziemssen, T, Reichmann, H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 74–80.CrossRefGoogle ScholarPubMed
Asahina, M, Vichayanrat, E, Low, DA, Iodice, V, Mathias, CJ. Autonomic dysfunction in parkinsonian disorders: Assessment and pathophysiology. J Neurol Neurosurg Psychiatry 2013; 84: 674–80.CrossRefGoogle ScholarPubMed
Lim, SY, Moro, E, Tan, AH, Lang, AE. Non-motor symptoms of Parkinson's disease and the effects of deep brain stimulation. In: Chaudhuri, , KR, Tolosa, , E, Schapira, , A, Poewe, , W, eds. Non-Motor Symptoms of Parkinson’s Disease, 2nd edn. Oxford:Oxford University Press, 2014; 394–419.Google Scholar
Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 3): S42–80.CrossRefGoogle ScholarPubMed
Jamnadas-Khoda, J, Koshy, S, Mathias, CJ, et al. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord 2009; 24: 1747–51.CrossRefGoogle ScholarPubMed
Low, PA, Gilden, JL, Freeman, R, Sheng, KN, McElligott, MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. JAMA 1997; 277: 1046–51.CrossRefGoogle ScholarPubMed
Freeman, R. Neurogenic orthostatic hypotension. N Engl J Med 2008; 358: 615–24.CrossRefGoogle ScholarPubMed
Low, PA, Singer, W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008; 7: 451–58.CrossRefGoogle ScholarPubMed
Metzler, M, Duerr, S, Granata, R, et al. Neurogenic orthostatic hypotension: Pathophysiology, evaluation, and management. J Neurol 2013; 260: 2212–9.CrossRefGoogle ScholarPubMed
Senard, JM, Chamontin, B, Rascol, A, Montastruc, JL. Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res 1992; 2: 99–104.CrossRefGoogle ScholarPubMed
Maule, S, Papotti, G, Naso, D, et al. Orthostatic hypotension: Evaluation and treatment. Cardiovasc Haematol Disord Drug Targets 2007; 7: 63–70.CrossRefGoogle ScholarPubMed
Perez-Lloret, S, Rey, MV, Fabre, N, et al. Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism Rel Disord 2012; 18: 501–5.CrossRefGoogle ScholarPubMed
Mostile, G, Jankovic, J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Related Disord 2009; 15 (Suppl. 3): S224–32.CrossRefGoogle ScholarPubMed
Schoffer, KL, Henderson, RD, O'Maley, K, O'sullivan, JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007; 22: 1543–9.CrossRefGoogle ScholarPubMed
Kaufmann, H, Freeman, R, Biaggioni, I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014; 83: 328–335CrossRefGoogle ScholarPubMed
Hoehn, MM. Levodopa-induced postural hypotension treatment with fludrocortisone. Arch Neurol 1975; 32: 50–1.CrossRefGoogle ScholarPubMed
Jankovic, J, Gilden, JL, Hiner, BC, et al. Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38–48.CrossRefGoogle ScholarPubMed
Corsini, GU, Del Zompo, M, Gessa, GL, Mangoni, A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979; 313: 954–6.CrossRefGoogle Scholar
Lang, AE. Acute orthostatic hypotension when starting dopamine agonist therapy in Parkinson disease: the role of domperidone therapy. Arch Neurol 2001; 58: 835.CrossRefGoogle ScholarPubMed
Hauser, RA, Hewitt, LA, Isaacson, S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2013; 4: 57–65.CrossRefGoogle Scholar
Sandroni, P, Opfer-Gehrking, TL, Singer, W, Low, PA. Pyridostigmine for treatment of neurogenic orthostatic hypertension: a follow-up survey study. Clin Auton Res 2005; 15: 51–3.CrossRefGoogle ScholarPubMed
Singer, W, Sandroni, P, Opfer-Gehrking, TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006; 63: 513–18.CrossRefGoogle ScholarPubMed
Shibao, C, Okamoto, LE, Gamboa, A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2010; 56: 847–51.CrossRefGoogle ScholarPubMed
Suchowersky, O, Furtado, S, Rohs, G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995; 10: 337–40.CrossRefGoogle ScholarPubMed
Lahrmann, H, Cortelli, P, Hilz, M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006; 13: 930–6.CrossRefGoogle ScholarPubMed
Ziemssen, T, Reichmann, H. Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord 2010; 3: 53–67.CrossRefGoogle ScholarPubMed
Sahul, ZH, Trusty, JM, Erickson, M, Low, PA, Shen, WK. Pacing does not improve hypotension in patients with severe orthostatic hypotension – a prospective randomized cross-over pilot study. Clin Auton Res 2004; 14: 255–8.CrossRefGoogle Scholar
Salat-Foix, D, Suchowersky, O. The management of gastrointestinal symptoms in Parkinson's disease. Expert Rev Neurother 2012; 12: 239–48.CrossRefGoogle ScholarPubMed
Stevens, JE, Jones, KL, Rayner, CK, Horowitz, M. Pathophysiology and pharmacotherapy of gastroparesis: Current and future perspectives. Expert Opin Pharmacother 2013; 14: 1171–86.CrossRefGoogle ScholarPubMed
Parkes, JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9: 517–32.CrossRefGoogle ScholarPubMed
Soykan, I, Sarosiek, I, Shifflett, J, Wooten, GF, McCallum, RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12: 952–7.CrossRefGoogle Scholar
Sakakibara, R, Kishi, M, Ogawa, E, et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinson’s Disease 2011; 924605.Google ScholarPubMed
Critchley, P, Langdon, N, Parkes, JD, et al. Domperidone. Br Med J 1985; 290: 788.CrossRefGoogle ScholarPubMed
Malek, NM, Grosset, KA, Stewart, D, Macphee, GJA, Grosset, DG. Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease. Parkinsonism Rel Disord 2013; 19: 586–9.CrossRefGoogle ScholarPubMed
Tack, J, Camilleri, M, Chang, L, et al. Systematic review: Cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012; 35: 745–67.CrossRefGoogle ScholarPubMed
Asai, H, Udaka, F, Hirano, M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 499–502.CrossRefGoogle ScholarPubMed
Pfeiffer, RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Rel Disord 2011; 17: 10–15.CrossRefGoogle ScholarPubMed
Jost, WH. Gastrointestinal dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 69–73.CrossRefGoogle ScholarPubMed
Bosshard, W, Dreher, R, Schnegg, JF, Bula, CJ. The treatment of chronic constipation in elderly people: An update. Drugs Aging 2004; 21: 911–30.CrossRefGoogle ScholarPubMed
Astarloa, R, Mena, MA, Sánchez, V, de la Vega, L, de Yébenes, JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992; 15: 375–80.CrossRefGoogle Scholar
Ashraf, W, Pfeiffer, RF, Park, F, Lof, J, Quigley, EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997; 12: 946–51.CrossRefGoogle ScholarPubMed
Ramkumar, D, Rao, SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936–71.CrossRefGoogle ScholarPubMed
Sturtzel, B, Mikulits, C, Gisinger, C, Elmadfa, I. Use of fiber instead of laxative treatment in a geriatric hospital to improve the wellbeing of seniors. J Nutr Health Aging 2009;13: 136–9.CrossRefGoogle Scholar
Muller, B, Assmus, J, Larsen, JP, et al. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurol Scand 2013; 127: 290–4.CrossRefGoogle ScholarPubMed
Eichhorn, TE, Oertel, WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16: 1176–7.CrossRefGoogle ScholarPubMed
Zangaglia, R, Martignoni, E, Glorioso, M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007; 22: 1239–44.CrossRefGoogle ScholarPubMed
Kirkman, MS, Zimmerman, DR, Filippini, SA. Marked deterioration in glycemic control with change in brand of lactulose syrup. South Med J 1995; 88: 492–3.CrossRefGoogle ScholarPubMed
Muller-Lissner, SA1, Kamm, MA, Scarpignato, C, Wald, A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232–42.CrossRefGoogle ScholarPubMed
Liu, Z, Sakakibara, R, Odaka, T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20: 680–6.CrossRefGoogle ScholarPubMed
Camilleri, M, Kerstens, R, Rykx, A, Vandeplassche, L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344–54.CrossRefGoogle ScholarPubMed
Cassani, E, Privitera, G, Pezzoli, G, et al. Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol Dietol 2011; 57: 117–21.Google ScholarPubMed
Ondo, WG, Kenney, C, Sullivan, K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012; 78: 1650–4.CrossRefGoogle ScholarPubMed
Sandyk, R, Gillman, MA. Colchicine ameliorates constipation in Parkinson's disease. J R Soc Med 1984; 77: 1066.Google ScholarPubMed
Sakakibara, R, Odaka, T, Lui, Z, et al. Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord 2005; 20: 261–2.CrossRefGoogle ScholarPubMed
Pfeiffer, RF, Markopoulou, K, Quigley, EM, Stambler, N, Cedarbaum, IM. Effect of NT-3 on bowel function in Parkinson's disease. Mov Disord 2002; 17: 223–4.Google Scholar
Chiu, CM, Wang, CP, Sung, WH, et al. Functional magnetic stimulation in constipation associated with Parkinson's disease. J Rehabil Med 2009; 41: 1085–9.CrossRefGoogle ScholarPubMed
Albanese, A, Brisinda, G, Bentivoglio, AR, Maria, G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003; 98: 1439–40.CrossRefGoogle ScholarPubMed
Cadeddu, F, Bentivoglio, AR, Brandara, F, et al. Outlet type constipation in Parkinson's disease: Results of botulinum toxin treatment. Aliment Pharmacol Ther 2005; 22: 997–1003.CrossRefGoogle ScholarPubMed
Mathers, SE, Kempster, PA, Law, PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989; 46: 1061–4.CrossRefGoogle ScholarPubMed
Edwards, LL, Quigley, EM, Harned, RK, Hofman, R, Pfeiffer, RF. Defecatory function in Parkinson's disease: Response to apomorphine. Ann Neurol 1993; 33: 490–3.CrossRefGoogle ScholarPubMed
South, AR, Somers, SM, Jog, MS. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology 2010; 74: 1198–202.CrossRefGoogle ScholarPubMed
Merello, M. Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management. Drugs Aging 2008; 25: 1007–19.CrossRefGoogle Scholar
Arbouw, MEL, Movig, KLL, Koopmann, M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: A randomized, double-blind, crossover trial. Neurology 2010; 74: 1203–7.CrossRefGoogle ScholarPubMed
Hyson, HC, Johnson, AM, Jog, MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17: 1318–20.CrossRefGoogle ScholarPubMed
Pfeiffer, RF. Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov Disord 2010; 25 (Suppl. 1): S94–7.CrossRefGoogle ScholarPubMed
Thomsen, TR, Galpern, WR, Asante, A, Arenovich, T, Fox, SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007; 22: 2268–73.CrossRefGoogle ScholarPubMed
Ondo, WG, Hunter, C, Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37–40.CrossRefGoogle ScholarPubMed
Guidubaldi, A, Fasano, A, Ialongo, T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord 2011; 26: 313–19.CrossRefGoogle ScholarPubMed
Postma, A-G, Heesters, MAAM, van Laar, T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord 2007; 22: 2430–5.CrossRefGoogle Scholar
Winge, K, Fowler, CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21: 737–45.CrossRefGoogle Scholar
Blackett, H, Walker, R, Wood, B. Urinary dysfunction in Parkinson's disease: a review. Parkinsonism Related Disord 2009; 15: 81–7.CrossRefGoogle ScholarPubMed
Nitti, V. Clinical testing for overactive bladder. Can Urol Assoc J 2011; 5 (Suppl.2): S137–8.CrossRefGoogle ScholarPubMed
Ouslander, JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002; 60 (Suppl. 1): 50–5.CrossRefGoogle ScholarPubMed
Cameron, AP, Jimbo, M, Heidelbaugh, JJ. Diagnosis and office-based treatment of urinary incontinence in adults. Part two: treatment. Ther Adv Urol 2013; 5: 189–200.CrossRefGoogle ScholarPubMed
Burgio, KL. Influence of behavior modification on overactive bladder. Urology 2002; 60 (Suppl. 1): 72–6.CrossRefGoogle ScholarPubMed
Vaughan, CP, Juncos, JL, Burgio, KL, et al. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011; 76: 1631–4.CrossRefGoogle ScholarPubMed
Appell, RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 2006; 66: 1361–70.CrossRefGoogle ScholarPubMed
Roth, B, Studer, UE, Fowler, CJ, Kessler, TM. Benign prostatic obstruction and Parkinson's disease: Should transurethral resection of the prostate be avoided? J Urol 2009; 181: 2209–13.CrossRefGoogle ScholarPubMed
Chandiramani, VA, Palace, J, Fowler, CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997; 80: 100–4.CrossRefGoogle Scholar
Giannantoni, A, Conte, A, Proietti, S, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol 2011; 186: 960–4.CrossRefGoogle ScholarPubMed
Kulaksizoglu, H, Parman, Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson's disease. Parkinsonism Rel Disord 2010; 16: 531–4.CrossRefGoogle Scholar
Brown, RG, Jahanshahi, M, Quinn, N, Marsden, CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990; 53: 480–86.CrossRefGoogle ScholarPubMed
Bronner, G. Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention. J Neurol Sci 2011; 310: 139–43.CrossRefGoogle ScholarPubMed
Bronner, G, Royter, V, Korczyn, AD, Giladi, N. Sexual dysfunction in Parkinson's disease. J Sex Marit Therapy 2004; 30: 95–105.CrossRefGoogle ScholarPubMed
Basson, R. Sexuality and Parkinson's disease. Parkinsonism Rel Disord 1996; 2: 177–85.CrossRefGoogle ScholarPubMed
Papatsoris, AG, Deliveliotis, C, Singer, C, Papapetropoulos, S. Erectile dysfunction in Parkinson's disease. Urology 2006; 67: 447–51.CrossRefGoogle ScholarPubMed
Cleeves, L, Findley, LJ. Bromocriptine induced impotence in Parkinson's disease. Br Med J 1987; 295: 367–8.CrossRefGoogle ScholarPubMed
Francis, ME, Kusek, JW, Nyberg, LM, Eggers, PW. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol 2007; 178: 591–6.CrossRefGoogle ScholarPubMed
Bronner, G. Practical strategies for the management of sexual problems in Parkinson's disease. Parkinsonism Rel Disord 2009; 15 (Suppl. 3): S96–100.CrossRefGoogle ScholarPubMed
Lim, SY, Evans, AH, Miyasaki, JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008; 1142: 85–107.CrossRefGoogle ScholarPubMed
Bronner, G, Vodusek, DB. Management of sexual dysfunction in Parkinson's disease. Ther Adv Neurol Disord 2011; 4: 375–83.CrossRefGoogle ScholarPubMed
Fine, J, Lang, AE. Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. Mov Disord 1999; 14: 701–3.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
O'sullivan, JD, Hughes, AJ. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998; 13: 536–9.CrossRefGoogle ScholarPubMed
Briganti, A, Salonia, A, Gallina, A. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2005; 2: 239–47.CrossRefGoogle ScholarPubMed
Hussain, IF, Brady, CM, Swinn, MJ, Mathias, CJ, Fowler, CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71: 371–4.CrossRefGoogle ScholarPubMed
Zesiewicz, TA, Helal, M, Hauser, RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000; 15: 305–8.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
Chrysant, SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 2013; 15: 475–83.CrossRefGoogle Scholar
Giammusso, B, Raffaele, R, Vecchio, I, et al. Sildenafil in the treatment of erectile dysfunction in elderly depressed patients with idiopathic Parkinson's disease. Arch Gerontol Geriatr Suppl 2002; 8: 157–63.CrossRefGoogle ScholarPubMed
Raffaele, R, Vecchio, I, Giammusso, B, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; 41: 382–6.CrossRefGoogle ScholarPubMed
Okun, MS, McDonald, WM, , R. DeLong, M. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol 2002; 59: 807–11.CrossRefGoogle ScholarPubMed
Okun, MS, Walter, BL, McDonald, WM, et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol 2002; 59: 1750–3.CrossRefGoogle ScholarPubMed
Okun, MS, Fernandez, HH, Rodriguez, RL, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD study. Arch Neurol 2006; 63: 729–35.CrossRefGoogle ScholarPubMed
Ready, RE, Friedman, J, Grace, J, Fernandez, H. Testosterone deficiency and apathy in Parkinson's disease: a pilot study. J Neurol Neurosurg Psychiatry 2004; 75: 1323–6.CrossRefGoogle ScholarPubMed
Witjas, T, Kaphan, E, Azulay, JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.CrossRefGoogle ScholarPubMed
Swinn, L, Schrag, A, Viswanathan, R, et al. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18: 1459–63.CrossRefGoogle ScholarPubMed

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×